Texas Pacific Land has increased revenues and net income by almost 12% in 2024, mainly driven by the 33% revenue growth in ...

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval- ...

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

Welcome Policy is a recreation fee subsidy to help Toronto residents access recreation programs. Eligible individuals and families will receive an annual financial credit that can be used towards the ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.3509 EPS, expectations were $0.99. Operator: Ladies and gentlemen, thank you ...

Royalty Pharma Plc (RPRX) reported its Q4 2024 earnings today, revealing earnings per share (EPS) of $0.3531, falling short of the forecasted $0.9849. The company also reported revenue of $594 million ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...